Literature DB >> 31840437

Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice.

Ye Wang1, Lei Deng1, Gilbert X Gonzalez1, Latika Luthra1, Chunhong Dong1, Yao Ma1, Jun Zou1, Sang-Moo Kang1, Bao-Zhong Wang1.   

Abstract

The development of a universal influenza vaccine is an ideal strategy to eliminate public health threats from influenza epidemics and pandemics. This ultimate goal is restricted by the low immunogenicity of conserved influenza epitopes. Layered protein nanoparticles composed of well-designed conserved influenza structures have shown improved immunogenicity with new physical and biochemical features. Herein, structure-stabilized influenza matrix protein 2 ectodomain (M2e) and M2e-neuraminidase fusion (M2e-NA) recombinant proteins are generated and M2e protein nanoparticles and double-layered M2e-NA protein nanoparticles are produced by ethanol desolvation and chemical crosslinking. Immunizations with these protein nanoparticles induce immune protection against different viruses of homologous and heterosubtypic NA in mice. Double-layered M2e-NA protein nanoparticles induce higher levels of humoral and cellular responses compared with their comprising protein mixture or M2e nanoparticles. Strong cytotoxic T cell responses are induced in the layered M2e-NA protein nanoparticle groups. Antibody responses contribute to the heterosubtypic NA immune protection. The protective immunity is long lasting. These results demonstrate that double-layered protein nanoparticles containing structure-stabilized M2e and NA can be developed into a universal influenza vaccine or a synergistic component of such vaccines. Layered protein nanoparticles can be a general vaccine platform for different pathogens.
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  broadly reactive immunity; immune cross-protection; layered protein nanoparticles; universal influenza vaccines

Mesh:

Substances:

Year:  2019        PMID: 31840437      PMCID: PMC6980908          DOI: 10.1002/adhm.201901176

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  51 in total

1.  Crystal structure of a naturally occurring parallel right-handed coiled coil tetramer.

Authors:  J Stetefeld; M Jenny; T Schulthess; R Landwehr; J Engel; R A Kammerer
Journal:  Nat Struct Biol       Date:  2000-09

Review 2.  CD4 T cell responses to influenza infection.

Authors:  Deborah M Brown; Eulogia Román; Susan L Swain
Journal:  Semin Immunol       Date:  2004-06       Impact factor: 11.130

Review 3.  Biomaterials for nanoparticle vaccine delivery systems.

Authors:  Preety Sahdev; Lukasz J Ochyl; James J Moon
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

4.  Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.

Authors:  Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Min-Chul Kim; Eun-Ju Ko; Jong Seok Lee; Youri Lee; Sang-Moo Kang
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

5.  Universal anti-neuraminidase antibody inhibiting all influenza A subtypes.

Authors:  Tracey M Doyle; Anwar M Hashem; Changgui Li; Gary Van Domselaar; Louise Larocque; Junzhi Wang; Daryl Smith; Terry Cyr; Aaron Farnsworth; Runtao He; Aeron C Hurt; Earl G Brown; Xuguang Li
Journal:  Antiviral Res       Date:  2013-09-30       Impact factor: 5.970

6.  Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans.

Authors:  Erika Assarsson; Huynh-Hoa Bui; John Sidney; Qing Zhang; Jean Glenn; Carla Oseroff; Innocent N Mbawuike; Jeff Alexander; Mark J Newman; Howard Grey; Alessandro Sette
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

7.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.

Authors:  Veit Hornung; Franz Bauernfeind; Annett Halle; Eivind O Samstad; Hajime Kono; Kenneth L Rock; Katherine A Fitzgerald; Eicke Latz
Journal:  Nat Immunol       Date:  2008-07-11       Impact factor: 25.606

8.  Virus-specific CD8+ T cells in primary and secondary influenza pneumonia.

Authors:  K J Flynn; G T Belz; J D Altman; R Ahmed; D L Woodland; P C Doherty
Journal:  Immunity       Date:  1998-06       Impact factor: 31.745

9.  Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers.

Authors:  Hongquan Wan; Hua Yang; David A Shore; Rebecca J Garten; Laura Couzens; Jin Gao; Lianlian Jiang; Paul J Carney; Julie Villanueva; James Stevens; Maryna C Eichelberger
Journal:  Nat Commun       Date:  2015-02-10       Impact factor: 14.919

Review 10.  M2e-Based Universal Influenza A Vaccines.

Authors:  Lei Deng; Ki Joon Cho; Walter Fiers; Xavier Saelens
Journal:  Vaccines (Basel)       Date:  2015-02-13
View more
  15 in total

1.  Influenza NP core and HA or M2e shell double-layered protein nanoparticles induce broad protection against divergent influenza A viruses.

Authors:  Yao Ma; Ye Wang; Chunhong Dong; Gilbert X Gonzalez; Yufeng Song; Wandi Zhu; Joo Kim; Lai Wei; Bao-Zhong Wang
Journal:  Nanomedicine       Date:  2021-11-04       Impact factor: 5.307

2.  Tyrosine-Based Cross-Linking of Peptide Antigens to Generate Nanoclusters with Enhanced Immunogenicity: Demonstration Using the Conserved M2e Peptide of Influenza A.

Authors:  Logan R Wilks; Gaurav Joshi; Megan R Grisham; Harvinder Singh Gill
Journal:  ACS Infect Dis       Date:  2021-08-25       Impact factor: 5.578

3.  SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice.

Authors:  Yao Ma; Ye Wang; Chunhong Dong; Gilbert X Gonzalez; Wandi Zhu; Joo Kim; Lai Wei; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Small       Date:  2022-05-23       Impact factor: 15.153

Review 4.  Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine.

Authors:  Christopher E Lopez; Kevin L Legge
Journal:  Vaccines (Basel)       Date:  2020-08-03

Review 5.  Prophylactic vaccine delivery systems against epidemic infectious diseases.

Authors:  Chao Pan; Hua Yue; Li Zhu; Guang-Hui Ma; Heng-Liang Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-07-17       Impact factor: 17.873

6.  Advanced drug delivery systems can assist in managing influenza virus infection: A hypothesis.

Authors:  Yinghan Chan; Sin Wi Ng; Meenu Mehta; Krishnan Anand; Sachin Kumar Singh; Gaurav Gupta; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Med Hypotheses       Date:  2020-09-24       Impact factor: 1.538

Review 7.  Promising Adjuvants and Platforms for Influenza Vaccine Development.

Authors:  Wandi Zhu; Chunhong Dong; Lai Wei; Bao-Zhong Wang
Journal:  Pharmaceutics       Date:  2021-01-07       Impact factor: 6.321

Review 8.  Influenza Vaccines toward Universality through Nanoplatforms and Given by Microneedle Patches.

Authors:  Sijia Tang; Wandi Zhu; Bao-Zhong Wang
Journal:  Viruses       Date:  2020-10-24       Impact factor: 5.048

Review 9.  Progress in the Development of Universal Influenza Vaccines.

Authors:  Wenqiang Sun; Tingrong Luo; Wenjun Liu; Jing Li
Journal:  Viruses       Date:  2020-09-17       Impact factor: 5.048

10.  Skin vaccination with dissolvable microneedle patches incorporating influenza neuraminidase and flagellin protein nanoparticles induces broad immune protection against multiple influenza viruses.

Authors:  Ye Wang; Song Li; Chunhong Dong; Yao Ma; Yufeng Song; Wandi Zhu; Joo Kim; Lei Deng; Timothy L Denning; Sang-Moo Kang; Mark R Prausnitz; Bao-Zhong Wang
Journal:  ACS Appl Bio Mater       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.